Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 272


Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis.

Kuykendall AT, Talati C, Padron E, Sweet K, Lancet JE, List AF, Sallman D, Komrokji RS.

Am J Hematol. 2019 Aug 23. doi: 10.1002/ajh.25625. [Epub ahead of print] No abstract available.


Prognostic significance of MYC oncoprotein expression on survival outcome in patients with acute myeloid leukemia with myelodysplasia related changes (AML-MRC).

Yun S, Sharma R, Chan O, Vincelette ND, Sallman DA, Sweet K, Padron E, Komrokji R, Lancet JE, Abraham I, Moscinski LC, Cleveland JL, List AF, Zhang L.

Leuk Res. 2019 Sep;84:106194. doi: 10.1016/j.leukres.2019.106194. Epub 2019 Jul 18.


Loss of Function of DOCK4 in Myelodysplastic Syndromes Stem Cells is Restored by Inhibitors of DOCK4 Signaling Networks.

Sundaravel S, Kuo WL, Jeong JJ, Choudhary GS, Gordon-Mitchell S, Liu H, Bhagat TD, McGraw KL, Gurbuxani S, List AF, Verma A, Wickrema A.

Clin Cancer Res. 2019 Sep 15;25(18):5638-5649. doi: 10.1158/1078-0432.CCR-19-0924. Epub 2019 Jul 15.


A phase 2 trial of the oral smoothened inhibitor glasdegib in refractory myelodysplastic syndromes (MDS).

Sallman DA, Komrokji RS, Sweet KL, Mo Q, McGraw KL, Duong VH, Zhang L, Nardelli LA, Padron E, List AF, Lancet JE.

Leuk Res. 2019 Jun;81:56-61. doi: 10.1016/j.leukres.2019.03.008. Epub 2019 Mar 30.


Cytokine-Regulated Phosphorylation and Activation of TET2 by JAK2 in Hematopoiesis.

Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo WL, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw KL, Bhattacharyya S, Bishop MR, Artz A, Thirman MJ, Moliterno A, Ji P, Levine RL, Godley LA, Steidl U, Bieker JJ, List AF, Saunthararajah Y, He C, Verma A, Wickrema A.

Cancer Discov. 2019 Jun;9(6):778-795. doi: 10.1158/2159-8290.CD-18-1138. Epub 2019 Apr 3.


S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes.

Cheng P, Eksioglu EA, Chen X, Kandell W, Le Trinh T, Cen L, Qi J, Sallman DA, Zhang Y, Tu N, Adams WA, Zhang C, Liu J, Cleveland JL, List AF, Wei S.

Leukemia. 2019 Aug;33(8):2034-2046. doi: 10.1038/s41375-019-0397-9. Epub 2019 Feb 8.


A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic Syndromes.

Komrokji RS, Wei S, Mailloux AW, Zhang L, Padron E, Sallman D, Lancet JE, Tinsley S, Nardelli LA, Pinilla-Ibarz J, Epling-Burnette PK, List AF.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):157-161. doi: 10.1016/j.clml.2018.12.005. Epub 2018 Dec 20.


TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.


Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.

Kuykendall AT, Talati C, Padron E, Sweet K, Sallman D, List AF, Lancet JE, Komrokji RS.

Am J Hematol. 2019 Jan;94(1):87-92. doi: 10.1002/ajh.25335. Epub 2018 Nov 25.


The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).

Sekeres MA, Swern AS, Giagounidis A, List AF, Selleslag D, Mittelman M, Schlegelberger B, Göhring G, Li JS, Sugrue MM, Fenaux P.

Blood Cancer J. 2018 Sep 21;8(10):90. doi: 10.1038/s41408-018-0126-z. No abstract available.


SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q.

Talati C, Sallman D, List AF.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):629-635. doi: 10.1016/j.clml.2018.07.293. Epub 2018 Jul 30. Review.


Assessment of ASC specks as a putative biomarker of pyroptosis in myelodysplastic syndromes: an observational cohort study.

Basiorka AA, McGraw KL, Abbas-Aghababazadeh F, McLemore AF, Vincelette ND, Ward GA, Eksioglu EA, Sallman DA, Ali NA, Padron E, Pinilla-Ibarz J, Komrokji R, Masala E, Santini V, Kosmider O, Fontenay M, Fenaux P, Sokol L, Wei S, Fridley B, List AF.

Lancet Haematol. 2018 Sep;5(9):e393-e402. doi: 10.1016/S2352-3026(18)30109-1. Epub 2018 Jul 30.


Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.

Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.


Association of EZH2 protein expression by immunohistochemistry in myelodysplasia related neoplasms with mutation status, cytogenetics and clinical outcomes.

McGraw KL, Nguyen J, Al Ali NH, Komrokji RS, Sallman D, Zhang X, Song J, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L.

Br J Haematol. 2019 Feb;184(3):450-455. doi: 10.1111/bjh.15099. Epub 2018 Jan 23. No abstract available.


Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.

Komrokji R, Garcia-Manero G, Ades L, Prebet T, Steensma DP, Jurcic JG, Sekeres MA, Berdeja J, Savona MR, Beyne-Rauzy O, Stamatoullas A, DeZern AE, Delaunay J, Borthakur G, Rifkin R, Boyd TE, Laadem A, Vo B, Zhang J, Puccio-Pick M, Attie KM, Fenaux P, List AF.

Lancet Haematol. 2018 Feb;5(2):e63-e72. doi: 10.1016/S2352-3026(18)30002-4. Epub 2018 Jan 10.


Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30.


Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.

Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Pogosov GL, Radich JP, Willman CL, Wood BL, Meshinchi S, Stirewalt DL.

Biopreserv Biobank. 2018 Feb;16(1):42-52. doi: 10.1089/bio.2017.0079. Epub 2017 Nov 27. Erratum in: Biopreserv Biobank. 2018 Apr;16(2):168.


The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.

Duong VH, Padron E, Al Ali NH, Lancet JE, Hall J, Kwok B, Zhang L, Epling-Burnette PK, List AF, Komrokji RS.

Ann Hematol. 2018 Feb;97(2):247-254. doi: 10.1007/s00277-017-3186-4. Epub 2017 Nov 22.


A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.

Mirza AS, Lancet JE, Sweet K, Padron E, Pinilla-Ibarz J, Nardelli L, Cubitt C, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):902-907. doi: 10.1016/j.clml.2017.09.007. Epub 2017 Sep 19.


The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. doi: 10.1016/j.clml.2017.08.002. Epub 2017 Aug 5.


Intrapatient functional clonality deconvoluted by coupling intracellular flow cytometry and next-generation sequencing in human leukemia.

Zhang Q, Ball MC, Zhao Y, Balasis M, Letson C, Vedder A, List AF, Epling-Burnette PK, Komrokji RS, Padron E.

Leukemia. 2018 Feb;32(2):532-538. doi: 10.1038/leu.2017.184. Epub 2017 Jun 21.


Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mittelman M, Muus P, Nimer SD, Hellström-Lindberg E, Powell BL, Guerci-Bresler A, Sekeres MA, Deeg HJ, Del Cañizo C, Greenberg PL, Shammo JM, Skikne B, Yu X, List AF.

J Hematol Oncol. 2017 Jun 26;10(1):131. doi: 10.1186/s13045-017-0491-2.


Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

Yoshimi A, Balasis ME, Vedder A, Feldman K, Ma Y, Zhang H, Lee SC, Letson C, Niyongere S, Lu SX, Ball M, Taylor J, Zhang Q, Zhao Y, Youssef S, Chung YR, Zhang XJ, Durham BH, Yang W, List AF, Loh ML, Klimek V, Berger MF, Stieglitz E, Padron E, Abdel-Wahab O.

Blood. 2017 Jul 27;130(4):397-407. doi: 10.1182/blood-2017-01-763219. Epub 2017 Jun 2. Erratum in: Blood. 2017 Sep 28;130(13):1602.


New Insight Into the Biology, Risk Stratification, and Targeted Treatment of Myelodysplastic Syndromes.

Haider M, Duncavage EJ, Afaneh KF, Bejar R, List AF.

Am Soc Clin Oncol Educ Book. 2017;37:480-494. doi: 10.14694/EDBK_175397.


Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP.

J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9.


Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.

Apuri S, Al Ali N, Padron E, Lancet JE, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):211-214. doi: 10.1016/j.clml.2016.10.003. Epub 2017 Jan 10.


Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.

Talati C, Zhang L, Shaheen G, Kuykendall A, Ball M, Zhang Q, Lancet JE, Zuckerman KS, List AF, Komrokji R, Moscinski L, Padron E.

Blood. 2017 Mar 30;129(13):1881-1883. doi: 10.1182/blood-2016-12-753210. Epub 2017 Feb 3. No abstract available.


Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP.

Oncotarget. 2017 Jan 24;8(4):6483-6495. doi: 10.18632/oncotarget.14130.


Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.

Griffin PT, Komrokji RS, Sweet K, Al Ali NH, Padron E, Kubal TE, List AF, Lancet JE.

Am J Hematol. 2017 Mar;92(3):232-237. doi: 10.1002/ajh.24627. Epub 2017 Feb 3.


The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.

Zhang L, McGraw KL, Sallman DA, List AF.

Leuk Lymphoma. 2017 Aug;58(8):1777-1790. doi: 10.1080/10428194.2016.1266625. Epub 2016 Dec 14. Review.


Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study.

Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ, Balasis ME, Mesa TE, Sallman DA, Lancet JE, Komrokji RS, List AF, McLeod HL, Alsina M, Baz R, Shain KH, Rollison DE, Padron E.

Lancet Oncol. 2017 Jan;18(1):112-121. doi: 10.1016/S1470-2045(16)30627-1. Epub 2016 Dec 4.


Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS).

Almeida A, Fenaux P, List AF, Raza A, Platzbecker U, Santini V.

Leuk Res. 2017 Jan;52:50-57. doi: 10.1016/j.leukres.2016.11.008. Epub 2016 Nov 13. Review.


Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.

Coombs CC, Sallman DA, Devlin SM, Dixit S, Mohanty A, Knapp K, Al Ali NH, Lancet JE, List AF, Komrokji RS, Padron E, Arcila ME, Klimek VM, van den Brink MR, Tallman MS, Levine RL, Rampal RK, Rapaport F.

Haematologica. 2016 Nov;101(11):e457-e460. Epub 2016 Jul 14. No abstract available.


When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia.

Ball M, List AF, Padron E.

Blood. 2016 Nov 17;128(20):2381-2387. Epub 2016 Oct 5. Review.


The NLRP3 inflammasome functions as a driver of the myelodysplastic syndrome phenotype.

Basiorka AA, McGraw KL, Eksioglu EA, Chen X, Johnson J, Zhang L, Zhang Q, Irvine BA, Cluzeau T, Sallman DA, Padron E, Komrokji R, Sokol L, Coll RC, Robertson AA, Cooper MA, Cleveland JL, O'Neill LA, Wei S, List AF.

Blood. 2016 Dec 22;128(25):2960-2975. doi: 10.1182/blood-2016-07-730556. Epub 2016 Oct 13.


Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide.

Negoro E, Radivoyevitch T, Polprasert C, Adema V, Hosono N, Makishima H, Przychodzen B, Hirsch C, Clemente MJ, Nazha A, Santini V, McGraw KL, List AF, Sole F, Sekeres MA, Maciejewski JP.

Leukemia. 2016 Dec;30(12):2405-2409. doi: 10.1038/leu.2016.228. Epub 2016 Aug 18. No abstract available.


Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.

Ramadan H, Duong VH, Al Ali N, Padron E, Zhang L, Lancet JE, List AF, Komrokji RS.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S64-6. doi: 10.1016/j.clml.2016.02.009.


Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology.

List AF, Kantarjian H, Freireich EJ.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S1. doi: 10.1016/j.clml.2016.07.001. No abstract available.


Improved intra-array and interarray normalization of peptide microarray phosphorylation for phosphorylome and kinome profiling by rational selection of relevant spots.

Scholma J, Fuhler GM, Joore J, Hulsman M, Schivo S, List AF, Reinders MJ, Peppelenbosch MP, Post JN.

Sci Rep. 2016 May 26;6:26695. doi: 10.1038/srep26695.


Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41.

Basiorka AA, McGraw KL, De Ceuninck L, Griner LN, Zhang L, Clark JA, Caceres G, Sokol L, Komrokji RS, Reuther GW, Wei S, Tavernier J, List AF.

Cancer Res. 2016 Jun 15;76(12):3531-40. doi: 10.1158/0008-5472.CAN-15-1756. Epub 2016 Apr 6.


Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.

McGraw KL, Nguyen J, Komrokji RS, Sallman D, Al Ali NH, Padron E, Lancet JE, Moscinski LC, List AF, Zhang L.

Haematologica. 2016 Aug;101(8):e320-3. doi: 10.3324/haematol.2016.143214. Epub 2016 Apr 14. No abstract available.


The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure.

Nazha A, Komrokji RS, Garcia-Manero G, Barnard J, Roboz GJ, Steensma DP, DeZern AE, Zell K, Zimmerman C, Ali NA, Jabbour E, Greenberg MD, Kantarjian HM, Maciejewski JP, List AF, Sekeres MA; MDS Clinical Research Consortium.

Haematologica. 2016 Jun;101(6):e224-7. doi: 10.3324/haematol.2015.140962. Epub 2016 Mar 18. No abstract available.


Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS).

Abel GA, Efficace F, Buckstein RJ, Tinsley S, Jurcic JG, Martins Y, Steensma DP, Watts CD, Raza A, Lee SJ, List AF, Klaassen RJ.

Haematologica. 2016 Jun;101(6):781-8. doi: 10.3324/haematol.2015.140335. Epub 2016 Mar 4.


Autoimmune diseases and myelodysplastic syndromes.

Komrokji RS, Kulasekararaj A, Al Ali NH, Kordasti S, Bart-Smith E, Craig BM, Padron E, Zhang L, Lancet JE, Pinilla-Ibarz J, List AF, Mufti GJ, Epling-Burnette PK.

Am J Hematol. 2016 May;91(5):E280-3. doi: 10.1002/ajh.24333. Epub 2016 Apr 4.


A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML).

Padron E, Dezern A, Andrade-Campos M, Vaddi K, Scherle P, Zhang Q, Ma Y, Balasis ME, Tinsley S, Ramadan H, Zimmerman C, Steensma DP, Roboz GJ, Lancet JE, List AF, Sekeres MA, Komrokji RS; Myelodysplastic Syndrome Clinical Research Consortium.

Clin Cancer Res. 2016 Aug 1;22(15):3746-54. doi: 10.1158/1078-0432.CCR-15-2781. Epub 2016 Feb 8.


Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.

Nazha A, Sekeres MA, Garcia-Manero G, Barnard J, Al Ali NH, Roboz GJ, Steensma DP, DeZern AE, Zimmerman C, Jabbour EJ, Zell K, List AF, Kantarjian HM, Maciejewski JP, Komrokji RS; MDS Clinical Research Consortium.

Leuk Res. 2016 Feb;41:43-7. doi: 10.1016/j.leukres.2015.12.007. Epub 2015 Dec 22.


Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.

List AF, Bennett JM, Sekeres MA, Skikne B, Fu T, Shammo JM, Nimer SD, Knight RD, Giagounidis A.

Leukemia. 2015 Dec;29(12):2452. doi: 10.1038/leu.2015.312. No abstract available.


Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.

Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw KL, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau MM, Steidl U, List AF, Evans T, Verma A, Wickrema A.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6359-68. doi: 10.1073/pnas.1516394112. Epub 2015 Nov 2.


Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes.

Komrokji RS, List AF.

Ann Oncol. 2016 Jan;27(1):62-8. doi: 10.1093/annonc/mdv488. Epub 2015 Oct 26. Review.


TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes.

McGraw KL, Cluzeau T, Sallman DA, Basiorka AA, Irvine BA, Zhang L, Epling-Burnette PK, Rollison DE, Mallo M, Sokol L, Solé F, Maciejewski J, List AF.

Oncotarget. 2015 Oct 27;6(33):34437-45. doi: 10.18632/oncotarget.5255.

Supplemental Content

Support Center